Premium
Real‐world, open‐label study to evaluate the effectiveness of mirtazapine on sleep quality in outpatients with major depressive disorder
Author(s) -
Wang Dan,
Li Zexuan,
Li Lingjiang,
Hao Wei
Publication year - 2014
Publication title -
asia‐pacific psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.654
H-Index - 21
eISSN - 1758-5872
pISSN - 1758-5864
DOI - 10.1111/appy.12060
Subject(s) - mirtazapine , insomnia , pittsburgh sleep quality index , major depressive disorder , sleep (system call) , medicine , sleep quality , polysomnography , sleep onset latency , antidepressant , psychiatry , apnea , amygdala , computer science , hippocampus , operating system
Abstract Introduction The objective of this study was to evaluate the effect of mirtazapine on sleep quality in real‐world outpatients with major depressive disorder ( MDD ). Methods Demographic characteristics of MDD outpatients were collected and the P ittsburgh S leep Quality I ndex ( PSQI ) was assessed before and after treatment. Results In 3,924 MDD outpatients after treatment, sleep efficiency was significantly higher ( P < 0.001), global PSQI score was significantly lower ( P < 0.01), the reduction rates of sleep latency ( P < 0.01) and global PSQI score ( P < 0.001) were notably higher, and the proportion of using sleep medications ( P < 0.05) was significantly lower in the mirtazapine group. In 3,455 MDD outpatients with insomnia after treatment, the reduction of sleep latency ( P < 0.001), the prolongation of sleep duration ( P < 0.001), and the increase in habitual sleep efficiency ( P < 0.001) were more obvious, the reduction rates of sleep latency ( P < 0.05) and global PSQI score ( P < 0.001) were significantly higher, and the proportion of using sleep medications ( P < 0.001) was significantly lower in the mirtazapine group. In 469 MDD outpatients without insomnia after treatment, the reduction of sleep latency ( P < 0.05), the increase in sleep duration ( P < 0.001) and habitual sleep efficiency ( P < 0.001), and the reduction rate of global PSQI score ( P < 0.05) were significantly greater in the mirtazapine group. Discussion This real‐world study suggests that mirtazapine improves sleep quality of MDD outpatients, and decreases the concomitant use of sleep medications.